MGMT and glioblastoma: Future studies aiming to predict MGMT promoter methylation status with radiomics should include homogeneous cohorts of glioblastoma patients and have a sufficiently large number of cases to permit a proper external validation; adherence to current reporting guidelines and radiomic pipelines (such as RQS, TRIPOD, and CLEAR [17, 22, 61]) should also be increased to improve quality, reliability, and, therefore, inter-study comparability.